NCT06796907 (BEHOLD-2) is a Phase 1, PHASE2 clinical trial of GSK5733584 in Tumours, Gynecological, sponsored by GlaxoSmithKline.

Who is sponsoring NCT06796907?

NCT06796907 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT06796907?

Interventions in NCT06796907: GSK5733584, Dostarlimab, Bevacizumab, Anticancer therapy 3, Anticancer therapy 4.

What condition does NCT06796907 study?

NCT06796907 studies Tumours, Gynecological.

Is NCT06796907 still recruiting?

NCT06796907 is currently recruiting now. Last updated 14 October 2025.

Last reviewed 2025-10-14 · How we verify

NCT06796907: BEHOLD-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors

Recruiting now Phase 1, PHASE2 Last updated 14 October 2025

What this trial tests

Phase 1, PHASE2 trial testing GSK5733584 in Tumours, Gynecological in 392 participants. Currently enrolling.

Timeline

4 March 2025

Primary endpoint
17 December 2027

5 April 2028

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	392
Start date	4 March 2025
Primary completion	17 December 2027
Estimated completion	5 April 2028
Sites	56 locations across Panama, Finland, Japan, Poland, South Korea, Denmark, Netherlands, Belgium

Drugs / interventions tested

GSK5733584 — full drug profile →
Dostarlimab
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Anticancer therapy 3 — full drug profile →
Anticancer therapy 4 — full drug profile →

Conditions studied

Tumours, Gynecological — all drugs for Tumours, Gynecological →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

18 and older, any sex, with Tumours, Gynecological. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at how safe and tolerable GSK5733584 is, how the body handles it, and how well it works when used with other cancer medicines. The study will include participants with advanced solid tumors who have either not responded to standard treatments or cannot tolerate them or have no available effective treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of GSK5733584

Trials testing the same drug.

NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT06431594 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Part · Phase 1 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06796907 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 14 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06796907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing